Quarterly Result29 May 2025, 06:22 pm
Procter & Gamble Health Ltd Reports 31% PAT Growth in Q3 and FY2024-25
AI Summary
Procter & Gamble Health Ltd announced its financial results for the Third Quarter and Financial Year ended March 31, 2025. The third quarter reported sales of ¥304 crores, up 23%, and PAT of ¥61 crore, up 31%. For the nine-month fiscal year ended March 31, 2025, the company recorded sales of ¥918 crores, up 8%, and PAT of ¥234 crores, up 27%. The company has changed its Financial Year from July 1 — June 30 to April 1 — March 31, and the results are indexed versus the comparable 9-month period in the last year. The Board of Directors has recommended a final dividend of 45% per Equity Share, making the total dividend payout for the fiscal 125 per share.
Key Highlights
- Procter & Gamble Health Ltd reports 31% growth in PAT for the quarter ended March 31, 2025.
- Sales for the third quarter were up 23% and for the nine-month fiscal year, sales were up 8%.
- The company's PAT for the nine-month fiscal year was up 27%, or 14% excluding one-time items.
- The company changed its Financial Year from July 1 — June 30 to April 1 — March 31.
- The Board of Directors has recommended a final dividend of 45% per Equity Share.